In this video interview, Anastasia Vasileva, MD, a researcher at the National Research Center for Hematology in Moscow, discusses findings from a study on adult patients with Ph-negative acute lymphoblastic leukemia (ALL) on the 2016M protocol presented at the 2025 European Hematology Association (EHA) Congress in Milan.
The RALL-2016m protocol, a low-intensity, prolonged treatment strategy for T-cell and B-cell acute lymphoblastic leukemia (ALL), aims to prevent relapse following initial therapy—a persistent challenge in both subtypes, according to Dr. Vasileva. The results showed that the therapy was safe and effective, the investigators wrote in their EHA abstract.
“The results show efficacy and an acceptable toxicity profile,” the researchers wrote. “Consolidation with blinatumomab for B-ALL with MRD persistence significantly improved the results and equalized the chances of patients with the group without persistent MRD. However, the addition of venetoclax to consolidation in T-ALL with MRD did not achieve such results.”
Reference
Gavrilina OA, Kotova E, Vasileva A. MRD-based target therapy for PH-Negative acute lymphoblastic leukemia in adult patients by the RALL-2016M protocol: effective for BCP-ALL, shows no efficacy in T-ALL. Abstract #PS1389. Presented at the European Hematology Association 2025 Congress; June 12-15, 2025; Milan, Italy.
